StreetAlpha.app
Home › Stocks › ASMB

Assembly Biosciences, Inc. (ASMB)

$22.19
▼ −1.38%
LAST CLOSE · NOV 20

Assembly Biosciences develops antiviral medicines for serious viral diseases, including genital herpes and hepatitis. It last closed at $22.19 on Nov 20, down 1.38% on the day. The next earnings report for ASMB is expected around Thu, Mar 18, 2027, after the close. For the quarter ended Sep 2026, ASMB reported EPS of -$0.93 on revenue of $3.0M, with revenue down 72.6% from a year ago. Over its last 8 reports the stock moved an average of 4.6% the session after earnings. Over the last 12 months ASMB insiders bought $0 of stock on the open market and sold $252K, according to SEC Form 4 filings.

AI Auto Pilots
Is ASMB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ASMB.

Key Stats

Last 12 months
Results
Revenue
$67.0M
+80.2% vs a year ago
Net income
−$11.1M
−16.6% margin
Free cash flow
−$40.7M
−60.7% margin
Operating margin
−31.8%
−$21.3M operating income
Valuation
Market cap
$454.4M
20.5M shares
P/E
–
Price to sales
6.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.1M
At Sep 30
Shareholder equity
$298.8M
Shares outstanding
20.5M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $6.3M$6.3MFY2021FY2022: $0$0FY2022FY2023: $7.2M$7.2MFY2023FY2024: $28.5M$28.5MFY2024FY2025: $72.3M$72.3MFY2025

From ASMB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 18
Estimated date · After the close
Reported EPS
-$0.93
Quarter ended Sep 2026
Year ago EPS
-$0.72
Same quarter last year
Revenue
$3.0M
−72.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.57Dec '24Mar 2025: -$1.17Mar '25Jun 2025: -$1.33Jun '25Sep 2025: -$0.72Sep '25Dec 2025: $2.48Dec '25Mar 2026: -$0.54Mar '26Jun 2026: -$0.20Jun '26Sep 2026: -$0.93Sep '26Latest -$0.93
Revenue by quarter
Dec 2024: $7.4MDec '24Mar 2025: $9.4MMar '25Jun 2025: $9.6MJun '25Sep 2025: $10.8MSep '25Dec 2025: $42.5MDec '25Mar 2026: $8.2MMar '26Jun 2026: $13.4MJun '26Sep 2026: $3.0MSep '26Latest $3.0M
How ASMB moved after its last 8 reports
Average move the session after a report ±4.6%
Nov 12, 2026After the close+4.7%
May 7, 2026After the close−3.9%
Mar 19, 2026After the close+3.5%
Nov 10, 2025After the close+3.3%
Aug 6, 2025After the close+9.2%
May 8, 2025After the close+5.0%
Mar 20, 2025After the close+3.0%
Nov 7, 2024After the close−4.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ASMBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ASMB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ASMB

Technical Analysis

ASMB · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock is 6% above its 20 day and 0% above its 50 day average. It is 21% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 53). The nearest support is the 50 day average at $22.17, and the nearest resistance the Pivot at $22.28.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 5.6%/day
Key levels
$39.7052 week high+78.9%
$26.74200 day average+20.5%
$25.88100 day average+16.6%
$22.70Pivot R1+2.3%
$22.69Swing high (Nov 11)+2.3%
$22.28Pivot+0.4%
$22.19Last close
$22.1750 day average−0.1%
$21.80Swing low (Oct 6)−1.8%
$21.78Pivot S1−1.8%
$20.9520 day average−5.6%
$19.2052 week low−13.5%
Indicators
RSI (14)53.38Middle of its rangeNeutral
MACD0.00Above its signal lineBullish
Stochastic73.5Middle of its rangeNeutral
ADX (14)22.0Weak trend
Williams %R-30.5Oversold below −80, overbought above −20Neutral
CCI (20)111.4Oversold below −100, overbought above 100Overbought
Rate of change+8.7%Change over 10 sessionsBullish
ATR (14)$1.25Typical daily range, 5.6% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for ASMB

What happened before

See how ASMB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ASMB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ASMB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ASMBHow many large options trades hit ASMB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ASMB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲71 buying vs 29 selling
  • ▲Held by funds +2.2 pts
  • ▲Funds holding +10
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10494+10.6%
In funds' top 1013−66.7%
Held by funds93.8%91.6%+2.2 pts
New / increased22 / 4932 / 35+6.0%
Reduced / sold out16 / 1317 / 15−9.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ASMB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ASMB Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$252K7 sales · 4 insiders
2026-03 sold $14K2026-06 sold $6742026-11 sold $238KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 2Jason A OkazakiCEO and PresidentSale6,202$19.62$122K
Nov 2Anuj GaggarChief Medical OfficerSale2,593$19.62$51K
Nov 2Nicole S WhiteChief Manufacturing OfficerSale2,593$19.62$51K
Nov 2Jeanette M BjorkquistPFO and PAOSale727$19.62$14K
Jun 17Jeanette M BjorkquistPFO and PAOSale29$23.25$674
Mar 30Nicole S WhiteChief Manufacturing OfficerSale197$26.69$5K
Every insider buy and sale for ASMB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ASMB insider trades →

From SEC Form 4 filings by ASMB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ASMB is in one of them and how their past ASMB trades turned out.

ASMB in the AI portfolios
Loading…

ASMB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ASMB in an article yet. Here's the latest on the wider market.

ASMB in the news

ASMB Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Feb 17
Who traded ASMB · since 2020
Latest 2 filings
$1K – $15KTraded Jan 4, 2021Filed Feb 17, 2021
$1K – $15KTraded Dec 28, 2020Filed Feb 10, 2021
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYSell$1K – $15KJan 4, 2021Feb 17, 202144 d
Christopher JacobsR · NYBuy$1K – $15KDec 28, 2020Feb 10, 202144 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Assembly Biosciences

Assembly Biosciences is a biotechnology company based in South San Francisco, California, that develops antiviral medicines for people with serious viral diseases. Its experimental treatments target genital herpes, hepatitis delta, hepatitis B and herpesviruses that can affect transplant patients. Gilead Sciences has licensed its genital herpes program, and the company is seeking partners for its hepatitis B candidate. Its other programs remain in clinical testing or early research.

Headquarters
South San Francisco, CA